Podcasts about mass general brigham

A large real-world study of over 1.2 million adults with type 2 diabetes found that SGLT2 inhibitors and GLP-1 receptor agonists reduced major cardiovascular events compared with metformin, while sulfonylureas and insulin increased risk. A separate French population study showed no association between first-trimester mRNA COVID-19 vaccination and congenital malformations, supporting vaccine safety in pregnancy. Finally, researchers at Mass General Brigham reported that large language models can produce “sycophantic” but incorrect medical advice, emphasizing the need for clinician oversight when using AI in healthcare.

In this episode of Bright Spots in Healthcare, we explore how human-centered design can uncover breakthrough solutions already hiding in plain sight. Dr. Kristian Olson, Vice President of Design Impact at Mass General Brigham and leader of the Springboard Studio, shares how slowing down to understand problems leads to faster, more effective innovation. The conversation dives into: The four pillars of effective healthcare innovation: design research, prototyping, supported implementation, and impact measurement How "stupidest ideas" exercises and question storming unlock creative solutions in frontline staff meetings Real results from Salem Hospital's mobility speedometer (300% increase in patient movement, reduced length of stay) The COVID testing booth prototype that saved $1 million per year while reducing gown usage by 97% Developing low-cost neonatal resuscitation devices in Uganda and India that improved ventilation skills Why frontline staff must be co-creators, not just implementers, of healthcare solutions This discussion offers practical frameworks for health plans, hospitals, and healthcare leaders looking to harness their teams' ingenuity and drive measurable improvement. Guest Bio: https://www.massgeneral.org/doctors/17235/kris-olson Resources & References MGB Springboard Studio: www.mgbbspringboardstudio.org Augmented Infant Resuscitator: ebinnovations.net Positive Deviance approach to solving malnutrition in Vietnam (referenced as inspiration) Partner with Bright Spots Ventures: If you are interested in speaking with the Bright Spots Ventures team to brainstorm how we can help you grow your business via content and relationships, email hkrish@brightspotsventures.com About Bright Spots Ventures: Bright Spots Ventures is a healthcare strategy and engagement company that creates content, communities, and connections to accelerate innovation. We help healthcare leaders discover what's working, and how to scale it. By bringing together health plan, hospital, and solution leaders, we facilitate the exchange of ideas that lead to measurable impact. Through our podcast, executive councils, private events, and go-to-market strategy work, we surface and amplify the "bright spots" in healthcare—proven innovations others can learn from and replicate. At our core, we exist to create trusted relationships that make real progress possible. Visit our website at www.brightspotsinhealthcare.com.

In this episode, Dr. Gregg Furie and Dr. Wynne Armand share how Mass General Brigham is leading the way in sustainable healthcare through renewable energy investments, emissions reduction, clinician engagement, and education. They discuss the system's progress toward net zero, the connection between climate and health, and practical steps for hospitals beginning their sustainability journey.

In this episode, Dr. Gregg Furie and Dr. Wynne Armand share how Mass General Brigham is leading the way in sustainable healthcare through renewable energy investments, emissions reduction, clinician engagement, and education. They discuss the system's progress toward net zero, the connection between climate and health, and practical steps for hospitals beginning their sustainability journey.

In this episode, Moderator Dr. Scott Weiner learns how Dr. Sarah E. Wakeman's innovative role unites diverse stakeholders to change both culture and practice in SUD care. We explore best practices for medication for opioid use disorder (MOUD), the development of unified IT tools, and the fine balance between clinical support and alert fatigue. Dr. Wakeman highlights the importance of data and quality dashboards, plus how Medicaid and state funding are leveraged to sustain impactful initiatives. The episode offers practical inspiration, showing how collaboration and the right incentives can drive value—and save lives.  What You'll Learn Strategies for building system-wide, holistic SUD initiatives. How to engage stakeholders across health systems, from clinicians to IT to state agencies. Best practices for developing and updating MOUD order sets. Approaches to increasing provider comfort with life-saving opioid treatments. The balance of clinical decision support and alert fatigue. The role of data dashboards in tracking SUD outcomes and quality measures. How to leverage Medicaid and state funds to support and expand treatment resources. Insights into risk contracts, funding streams, and statewide efforts to prevent overdose deaths. Why this challenging work is both challenging and rewarding!  MODERATOR: Scott Weiner, MD, MPH, FAAEM, FACEP, FASAM Emergency and Addiction Medicine Physician, Brigham and Women's Hospital Associate Professor, Harvard Medical School  Dr. Weiner is the McGraw Distinguished Chair in the Department of Emergency Medicine at Brigham and Women's Hospital and an Associate Professor of Emergency Medicine at Harvard Medical School. He is board-certified in emergency medicine and addiction medicine. He is an active researcher, working on multiple projects that focus on prevention and treatment of opioid use disorder.  GUEST: Sarah Elizabeth Wakeman, MD Medical Director for Substance Use Disorder at Mass General Brigham Medical Director for the Mass General Hospital Substance Use Disorder Initiative Program director of the Mass General Addiction Medicine fellowship Associate Professor of Medicine at Harvard Medical School  Sarah E. Wakeman, MD is the Senior Medical Director for Substance Use Disorder at Mass General Brigham in the Office of the Chief Medical Officer, Medical Director for the Mass General Hospital Program for Substance Use & Addiction Services, Program Director of the Mass General Addiction Medicine fellowship, and an Associate Professor of Medicine at Harvard Medical School. She received her A.B. from Brown University and her M.D. from Brown Medical School. She completed residency training in internal medicine and served as Chief Medical Resident at Mass General Hospital. She is a diplomate and fellow of the American Board of Addiction Medicine and board certified in Addiction Medicine by the American Board of Preventive Medicine. Clinically she provides specialty addiction and general medical care in the inpatient and outpatient setting at Mass General Hospital and the Mass General Charlestown Health Center. Her research interests include integrated substance use disorder treatment in general medical settings, low threshold treatment models, and opioid use disorder treatment. 

Dr. Stephen Dorner, a leader for Mass General Brigham's home hospital program, discusses the impact of the government shutdown.

We kicked off the program with four news stories and different guests on the stories we think you need to know about!The disappearance of Christopher Bird…disappeared on Sunday, July 29, 1984. He was last seen by a friend at the D&Q Stables in Windham. Guest: Emily Sweeney – Boston Globe Cold Case Files Reporter & Blotter Tales columnist Mass General Brigham will soon bill you when your doctor consults a specialist about your care. Guest: Jonathan Saltzman – Boston Globe reporter Gov. Maura Healey releases ‘vision' for statewide high school graduation requirements Guest: Chris Van Buskirk – State House Reporter for the Boston Herald What is the disorder PANDAS or PANS? 33,000 (or one in 200) children in Massachusetts suffer today from what is now known as Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (P.A.N.D.A.S.) or Pediatric Acute-onset Neuropsychiatric Syndrome (P.A.N.S). -Upcoming Walk – Making Strikes for PANS & PANDAS. Saturday, Oct. 4 – Boston Common. Guest: Jennifer Vitelli – Executive Director of the Look Foundation – also her son has PANDAS  

So on April 22, 2015, a four-day-old baby girl in Boston, let's call her baby Maria, became the first healthy infant in human history to have her genome comprehensively sequenced, comprehensively analyzed, as part of a clinical controlled trial in preventive genomics.2015年4月22日，在波士顿，一名只有四天大的女婴——我们姑且称她为玛丽亚宝宝——成为人类历史上第一位健康婴儿，她的基因组在一项预防性基因组学的临床对照试验中被全面测序并进行全面分析。Now, why is this important? It's great to be first, but it's important because when children are ill, everybody's upset. But when children remain ill and doctors can't figure out what's going on, well, that casts their parents into a diagnostic odyssey that can take years and be incredibly agonizing. It can create all sorts of misunderstanding, misdiagnosis and mismanagement.那么，为什么这很重要呢？成为“第一”固然值得称道，但更重要的是，当孩子生病时，全家都会陷入焦虑。而当孩子长期患病而医生却无法找出病因时，父母就会踏上一段漫长而痛苦的“诊断奥德赛”，这种折磨可能持续多年。它会带来各种误解、误诊，甚至错误治疗。Now, sometimes those children will go on to get genetic testing, and sometimes they'll find an answer. And sometimes those answers mean that you can treat the child, but by then it can be too late. The damage is permanent. This is particularly tragic because there are so many treatable genetic conditions today, and they're going to be even more with gene editing, cell and gene therapies. In fact, it's been suggested that over 90 percent of genetic conditions will be treatable in the next few years with gene editing.有时候，这些孩子最终会接受基因检测，有时候能找到答案。而有时这些答案意味着孩子是可以治疗的，但等到那时，往往已经为时已晚，损害不可逆转。这尤其令人痛心，因为如今已有许多遗传性疾病是可治疗的，而随着基因编辑、细胞与基因疗法的发展，可治疗的遗传病将会更多。事实上，有人预测，在未来几年内，超过90%的遗传性疾病都将通过基因编辑得到治疗。So the key to this is obviously finding these children early, actually analyzing their DNA at or shortly after birth. And so ten years ago, I pulled together a team at Harvard Medical School, Mass General Brigham, Broad Institute, Ariadne Labs, and got together with a brilliant group of co-leaders: Alan Beggs, Amy McGuire, Heidi Rehm and Ingrid Holm. And together, we launched the BabySeq or Baby Sequencing Project, the world's first trial of newborn genomic sequencing.因此，关键显然在于尽早发现这些孩子，在出生时或出生后不久就对他们的DNA进行分析。于是十年前，我在哈佛医学院、麻省总医院、布罗德研究所和阿里阿德涅实验室组建了一支团队，并与一群杰出的共同领导者——艾伦·贝格斯、艾米·麦奎尔、海蒂·雷姆和英格丽德·霍尔姆——携手合作。我们共同启动了“婴儿基因组测序计划”（BabySeq Project），这是世界上第一个针对新生儿进行基因组测序的试验。Now, when we presented this information at medical meetings, we didn't quite get the reaction we were hoping for.然而，当我们在医学会议上展示这些成果时，却并没有得到我们所期望的反应。

Novel Imaging Techniques and Phenotypes in Asthma and COPD

Welcome back to Ozempic Weightloss Unlocked, the podcast dedicated to bringing you the latest news, updates, and insights on Ozempic and its impact on weight, health, and lifestyle.Today, we start with the basics: Ozempic is a medication based on semaglutide, and it is part of a class of drugs called GLP-1 receptor agonists. These drugs work by mimicking a hormone in your gut that helps regulate blood sugar and appetite. According to Purdue University, after a meal, the body naturally releases GLP-1, which helps stimulate insulin production and signals the brain to feel full. Ozempic uses a modified version of this hormone, which not only lowers blood sugar but also reduces appetite, leading to significant weight loss. Clinical studies suggest people can lose between five and twelve percent of their body weight, while also seeing improvements in blood sugar and cardiovascular health.Ozempic is recommended as the first injectable therapy for diabetes by the American Diabetes Association, but most of its headline-grabbing popularity now comes from its off-label use for weight loss. Over fifteen million adults in the United States now use medications like Ozempic, Wegovy, or similar GLP-1-based drugs. The Wall Street Journal reports that this number has been climbing steadily each year.But as more people turn to Ozempic, new challenges and concerns are emerging. The most common side effects are nausea and digestive issues, which can be so severe that up to forty percent of people stop using the drug within the first month, according to Tufts University researchers. Even for those who tolerate Ozempic, there are drawbacks. Experts at Purdue University caution that weight often returns when the drug is discontinued, meaning it is not a permanent fix. Other concerns are rising as well. Mass General Brigham recently published research in JAMA Ophthalmology that links semaglutide to a greater risk of non-arteritic anterior ischemic optic neuropathy, a condition that can cause sudden, permanent blindness. People with diabetes taking semaglutide were over four times more likely to develop this disorder than those who did not.At the same time, there is a lot of online buzz around microdosing, or taking very small amounts of GLP-1 drugs for longevity or anti-aging. The Washington Post and The Independent have both reported that leading experts see no solid scientific evidence that microdosing these drugs provides any benefit or is even safe. Companies marketing microdosing protocols are ahead of the actual science.Researchers at Tufts are now developing new medications that target even more hormone receptors, hoping to be more effective, easier to take, and come with fewer side effects. Their most recent breakthrough aims for a four-in-one drug that tackles multiple hormones tied to metabolism and appetite, with the goal of delivering even greater and longer-lasting weight loss. The hope is that future drugs could treat obesity and simultaneously reduce risks for over one hundred eighty diseases linked to excess weight, including diabetes, cancer, and heart disease.Meanwhile, there are also efforts to stimulate the body's own GLP-1 production naturally, possibly through dietary fibers or future supplements. Purdue researchers believe this could help people maintain weight loss after coming off Ozempic, without the harsh side effects of injections, though results so far show milder weight control than with the actual drug.To sum up, Ozempic has opened a new chapter in metabolic medicine, but there are still risks, unanswered questions, and an ever-changing landscape as science races forward. We will be here to keep you informed with the latest evidence and expert insights.Thank you for tuning in to Ozempic Weightloss Unlocked. If you found this episode helpful, please subscribe so you do not miss our future updates and expert interviews. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Send us a textIn this episode of Causes or Cures, Dr. Eeks chats with Dr. Jerry Avorn, a Professor of Medicine at Harvard Medical School, drug safety watchdog, and author of Rethinking Medications: Truth, Power, and the Drugs You Take. If you've ever felt uneasy about the rising cost of prescription drugs, the process or speed by which new meds are approved, or why the side effects list is longer than your grocery receipt, this episode is for you.Dr. Avorn pulls no punches. We talk about:How our current system rewards speed over evidence, and why “accelerated approval” may sound good but can lead to disaster.The rise of drugs approved with weak or surrogate endpoints, yet priced like gold (yep, you still pay full price for half-baked science).Shocking case studies, like the Vioxx heart attack debacle and the controversial Alzheimer's drug Aduhelm.The FDA's evolution from watchdog to lapdog (in some cases).Conflicts of interest.Public funding, private profits: how taxpayer money fuels breakthroughs that we can't afford. (WTF!)And, yes, we talk about the “Do Your Own Research” crowd.Dr. Avorn's mission? Help patients and doctors actually understand what they're taking or prescribing, and what forces are shaping those decisions.Why listen?Because behind every pill is a story, and it's not always the one you're told in the ad with the beach scene and happy jazz flute.Links:Grab the book: Rethinking Medications: Truth, Power, and the Drugs You Take (Simon & Schuster, 2025)Jerry Avorn, MD, is a professor of medicine at Harvard Medical School and a senior internist in the Mass General Brigham health-care system. He built a leading research center at Harvard to study medication use, outcomes, costs, and policies and developed the educational approach of “academic detailing” to provide evidence-based information about medications to prescribers. One of the nation's most highly cited researchers, Dr. Avorn is the author of Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, and he has written or cowritten over six hundred papers in the medical literature as well as commentaries in the New York Times, The Washington Post, JAMA, and The New England Journal of Medicine.You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here! (Now featuring interviews with top experts on health you care about!)Support the show

NBC10 Boston's Sue O'Connell guest hosts with Jim. NAACP's Michael Curry on how Trump is replacing "woke" with his own version of diversity, plus a mini-lesson on the history of white supremacy, in today's context. Boston Globe business columnist Shirley Leung on whether Mayor Wu has paid enough attention to the city center and the Connecticut Sun WNBA team potentially moving to Boston.Boston Medical Center's Dr. Katherine Gergen Barnett on the return of the presidential fitness test, CVS and Mass General Brigham expanding primary care in Mass., and what's needed to actually expand IVF access. Tufts food policy analyst Corby Kummer on the vodka-energy drink mix up, how food stamp cuts could hurt local grocers, and where to find the best ice cream in the state. 

In this episode, Amy E. Lee, President and COO of Nantucket Cottage Hospital, shares how her team is expanding access, strengthening workforce sustainability, and leveraging technology to deliver high-quality care 30 miles out to sea. She also discusses housing challenges, talent development, and the hospital's strategic role within the Mass General Brigham system.

WBZ NewsRadio's Madison Rogers reports.

Validation of AHA PREVENT in healthcare populations| JACC Deep Dive In this JACC Deep Dive, JACC Editor in Chief Harlan M. Krumholz, MD, SM, explores a study led by Dr. Pradeep Natarajan that evaluates how well the new AHA PREVENT risk equations predict cardiovascular events across four major U.S. health systems. The study found wide variation in performance—PREVENT was well-calibrated at Penn Medicine but significantly underestimated risk at Mass General Brigham and Vanderbilt, particularly among women and minority groups. Reviewers praised the importance and rigor of the work but raised key questions about model calibration, fairness in outcome comparisons, and whether truly "plug-and-play" risk tools are realistic across diverse healthcare environments.

Colorectal cancer is showing up more often in younger generations, such as millennials. This type of cancer is the second-leading cause of cancer death, but it's also easily preventable with regular screenings. It can be challenging for people in underserved communities to get access to these screenings, or even learn about them, so Mass General Brigham is making an effort to get the word out. Dr. Allison Bryant, MGB's Associate Chief Health Equity Officer, returns to the show this week to share information about this important campaign.

School is out for the summer, and for most teens, that means unlimited access to doom scrolling and binge watching! And while a little celebratory, post-exam screen time is warranted, the slippery slope of a constant screen in your teen's face presents real threats to their emotional and behavioural development. But how do we get ahead of the algorithms that are designed to keep its users engaged for hours? And how do we set a better example for our teens as we navigate how to mitigate our own over-use? Host Pooja Handa speaks to Dr. Alexandra Gold, Licensed Clinical Psychologist at Mass General Brigham and Faculty at Harvard Medical School, about tangible steps towards a more healthy relationship between your teenager and their devices.We love feedback at The Big Story, as well as suggestions for future episodes. You can find us: Through email at hello@thebigstorypodcast.ca  Or @thebigstoryfpn on Twitter

In this episode of SoundPractice, we dive into an engaging and informative discussion on the future of AI in healthcare and its implications for both doctors and patients. Host Mike Sacopulos is joined by Laura Landro to explore the emerging world of ambient listening technology. Laura Landro, an award-winning writer and journalist, former Wall Street Journal “Informed Patient” columnist, and author of Survivor: Taking Control of Your Fight Against Cancer, brings an innovative perspective on medical technology advancements. This technology captures clinician-patient conversations, aiming to alleviate documentation burdens, enhance patient care, and reduce clinician burnout. However, it also raises important concerns about privacy and data security. Tune in to learn how leading institutions are pioneering research while ethical considerations continue to shape its future, especially in sensitive areas of healthcare. Episode Highlights: • Research Insights: Discover the benefits that institutions like Mass General Brigham are experiencing in terms of cost and time savings, and improved quality of care. • Regulatory and Liability Concerns: Explore the potential need for FDA oversight if the technology influences clinical decisions, and the implications of errors in AI-generated documentation. • Initial Patient Reactions: Gain first-hand insights from patients, including those who find the technology beneficial and others who have privacy concerns. • Future Outlook: Project how ongoing development and ethical considerations will shape the integration of AI in healthcare. Resources • Laura Landro's WSJ Article: Why AI May Be Listening In On Your Next Doctor's Appointment - https://www.wsj.com/health/healthcare/ai-ambient-listening-doctor-appointment-e7afd587 • Book by Laura Landro: Survivor: Taking Control of Your Fight Against Cancer - https://www.amazon.com/Survivor-Taking-Control-against-Cancer/dp/0684856786 Learn more about the American Association for Physician Leadership at https://www.physicianleaders.org/

In this episode, Dr. Nadia Khalil interviews Dr. Nathaniel Robbins, the Director of the Autonomic and Small Fiber Neuropathy program at Mass General Brigham, on POTS. In this episode, they review the diagnostic criteria, clinical presentation, differential diagnosis, adjunctive testing, and management.

In this episode, Dr. John Patrick Co and Dr. Jason Morris of Mass General Brigham share insights on the system's integrated approach to graduate medical education. They discuss the benefits of cross-institutional training, overcoming operational and cultural challenges, and strategies for sustainable growth while keeping trainees' experiences at the center.

Tune in for today's industry updates.

If you're tired of picking apart your appearance, hiding your body, or never feeling good enough, this episode is for you. Today, you'll learn the 4 simple steps you can take to build lasting confidence and finally feel good in your body. This powerful episode was inspired by a raw and emotional conversation Mel had with viral comedian Jake Shane. When Jake admitted he hates how he looks and struggles with self-worth, it opened the door to a bigger truth: millions of people feel the exact same way—but don't know what to do about it. So, Mel called in the experts. In this episode, you'll hear from Mel and Jake and learn tools from two renowned psychiatrists: -Dr. Judith Joseph, MD, double board-certified psychiatrist, professor at Columbia and NYU Medical Schools, and author of the bestselling book High Functioning. -Dr. Ashwini Nadkarni, MD, Harvard Medical School professor and psychiatrist at Mass General Brigham who specializes in anxiety, OCD, PTSD, and depression. Together, they break down the surprising psychology behind body shame and give you a practical, proven roadmap to feeling better, starting now. You'll learn how to: Break free from body shame, obsession, and constant comparisonRewire your brain for confidence and lasting self-acceptanceUse 4 science-backed steps to heal how you see yourselfUnderstand the hidden psychology behind body image and self-talkUnpack the shocking research on how screens and modern life are distorting your self-image (and how to fix it)This isn't just a conversation. It's your roadmap to healing, backed by science.  After listening you will have the tools, the science, and the mindset shift you need to stop hiding—and start seeing yourself clearly. Because when you change how you see yourself, you change everything. For more resources, click here for the podcast episode page. If you liked this episode, you'll love listening to this one next: How to Build Real Confidence: 7 Truths to Unlock Your Authentic SelfConnect with Mel:  Get Mel's #1 bestselling book, The Let Them TheoryWatch the episodes on YouTubeFollow Mel on Instagram The Mel Robbins Podcast InstagramMel's TikTok Sign up for Mel's personal letter Subscribe to SiriusXM Podcasts+ to listen to new episodes ad-freeDisclaimer

On today's episode, the team is joined by Hamid Tabatabaie, President & CEO of CodaMetrix, a Series B HealthTech company using AI to transform clinical coding.Hamid brings deep experience from the healthcare technology space and has been at the forefront of driving operational efficiencies in some of the most complex health systems in the U.S.The conversation kicks off with a look into Hamid's background, followed by an overview of CodaMetrix, how it began, what problem it solves, and why it matters.Key Discussion Points:

Update on Pulmonary Function Test Interpretation

Visste du att Sverige är världsledande i att trycka på snooze och somna om. I kvällens avsnitt hör du historierna om när vi kanske tryckte en gång för mycket. Lyssna på alla avsnitt i Sveriges Radio Play. Det är forskare vid amerikanska Mass General Brigham som har studerat sömndata från 21 000 personer över hela världen och har bland annat kommit fram till att vi i Sverige tillsammans med USA och Tyskland är de flitigaste användarna av snooze.Vi i Sverige snittar på 2,7 tryck per morgon. Forskningen visar också att personer som lägger sig tidigt snoozar mindre, medan man ser ett samband mellan att man lägger sig sent så används snooze funktionen mer frekvent. Vad säger vi nattugglor om det månne?Christian Olsson om försovningar vi minns Ring oss, mejla på karlavagnen@sverigesradio.se eller skriv till oss på Facebook och Instagram. Slussen öppnar klockan 21:00 och programmet börjar kl. 21:40.

The Department of Health and Human Services cancels Moderna's multi-million-dollar award to develop an mRNA vaccine for influenza, including bird flu. CVS and Express Scripts sue Arkansas over state law restricting pharmacy benefit managers. And, a new study from Mass General Brigham finds that traditional diagnostic tools outperformed generative AI. Those stories coming up on today's episode of the Gist Healthcare podcast. Hosted on Acast. See acast.com/privacy for more information.

In this NightSide News Update we chatted with: Alan Arnette, a mountaineer and climbing coach with over 30 years climbing experience – Discussing challenges climbing Mt. Everest and the cost.Dr. Rebecca Robbins, a sleep expert and researcher at Mass General Brigham and Harvard Medical School - Discussing how hitting the snooze button might not be in your best interest!Dr. David Hill, member of the Lung Association's National Board of Directors, immediate past chair of the Northeast Regional Board of the American Lung Association, and a practicing pulmonary and critical care physician - Discussing the results from the 2025 “State of the Air” report done by the American Lung Association.John Judge, CEO of Scouting Boston - Discussing Scouting America and Scouting Boston name change and upcoming event honoring two outstanding supporters.You can hear NightSide with Dan Rea, Live! Weeknights From 8PM-12AM on WBZ NewsRadio on the #iHeartRadio app!

Andrew Mahler, Vice President of Privacy and Compliance Services, Clearwater, speaks with Kathleen Healy, Partner, Robinson Cole, and Robert Martin, Senior Legal Counsel, Mass General Brigham, about how health care compliance teams can build effective governance models, monitor legal risks, and prepare for enforcement activity related to artificial intelligence (AI). They discuss how to build an effective AI oversight framework and assess AI systems for bias and transparency, compliance considerations related to the Health Insurance Portability and Accountability Act and the 21st Century Cures Act, what federal agencies are signaling in terms of their AI priorities, and future trends shaping AI compliance in health care. Kate and Robert spoke about this topic at AHLA's 2025 Complexities of AI in Health Care conference in Orlando, FL. Sponsored by Clearwater. AHLA's Health Law Daily Podcast Is Here! AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this new podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.

Johnny Mac shares five positive news stories to brighten your Memorial Day weekend. Highlights include a new AI tool called Face Age by Mass General Brigham that predicts biological age from selfies, Harvard Law School's discovery of a genuine Magna Carta, comedian Sebastian Fowler's 3,333-mile cross-country BMX ride for charity, the precision of a new atomic clock called NIST-F4, and the adventurous tale of a loose pet kangaroo named Irwin. Get the show without ads. Five bucks.  For Apple users, hit the banner on your Apple podcasts app which says UNINTERRUPTED LISTENING. For Spotify or other players, visit caloroga.com/plus.   

Send us a textThe leap from neurology residency to attending brings a critical decision - fellowship training or direct practice? In this compelling episode, Harvard neurologists Dr. Galina Gheihman and Dr. Denis Balaban share their contrasting post-residency paths, offering a roadmap for trainees wrestling with their next career steps.This conversation offers honest, practical guidance for navigating the post-residency landscape. Whether you're considering fellowship, direct practice, academic medicine, or industry roles, you'll gain valuable perspective on aligning your next steps with your true professional passions.• Transitioning from resident to attending involves complex role adjustments, especially when supervising former colleagues• Establishing clinical independence requires navigating new responsibilities in outpatient care and deciding when to manage vs. when to refer• Early career physicians lose the built-in cohort of training years precisely when facing critical career decisions• Building support networks through regular check-ins with division chairs and connecting with fellow educators becomes essential• Medical education lacks structured preparation for the business aspects of medicine including salary negotiation and career advancement• Embracing uncertainty and having honest conversations with patients about complex cases is integral to neurology practice• The most fulfilling aspects of attending life include the teaching-clinical intersection and helping patients navigate fear and uncertaintySupport the showHosts:Dr. Nupur Goel is a second-year neurology resident at Mass General Brigham in Boston, MA. Follow Dr. Nupur Goel on Twitter @mdgoels Dr. Blake Buletko is a vascular neurologist and program director of the Adult Neurology Residency Program at the Cleveland Clinic in Cleveland, OH. Follow Dr. Blake Buletko on Twitter @blakebuletko Follow the Neurophilia Podcast on Twitter and Instagram @NeurophiliaPod

Today's episode is going to focus on management of patellar instability – including nonsurgical treatment, MPFL reconstruction techniques and the addition of other procedures including trochleoplasty and osteotomies. We are joined today by two outstanding guests!  Dr. Miho Tanaka is a Professor of Orthopedic Surgery at Harvard Medical School and the Director of the women sports medicine program at Mass General Brigham.  She is also the head team physician for the New England Revolution and team physician for the Boston Red Sox, Boston ballet and Boston Glory.Dr. Beth Shubin Stein is an orthopaedic surgeon at the Hospital for Special Surgery and Professor of Orthopaedic Surgery at Weill Cornell Medical College. She is also the Co-Director of the women's sports medicine center at HSS and the Director of the Patellofemoral Center at HSS.So, without further ado, let's get to the Field House!

This week, Dr. Sigman is joined by Dr. Augustus Mazzocca, Medical Director at Mass General Brigham and Faculty at Harvard Medical School. Here, they discuss his journey into orthopedics in this episode recorded live at Shoulder360 in Miami Beach, Florida.

Send us a textThe leap from neurology residency to attending brings a critical decision - fellowship training or direct practice? In this compelling episode, Harvard neurologists Dr. Galina Gheihman and Dr. Denis Balaban share their contrasting post-residency paths, offering a roadmap for trainees wrestling with their next career steps.Dr. Gheihman opted to bypass traditional fellowship, instead pursuing a "primary care neurology" role while simultaneously earning a master's in medical education. Her candid perspective on readiness resonates deeply: "You aren't confident, but you are competent - and there's a difference." For those intimidated by independent practice, she provides practical strategies for managing the transition and emphasizes that general neurology remains a fulfilling, academically rich career path.Meanwhile, Dr. Balaban shares his journey through multiple fellowships, including a rare industry-sponsored position that offered unprecedented insights into pharmaceutical medicine. His behind-the-scenes look at clinical trials, drug development timelines, and the physician's role in industry pulls back the curtain on career possibilities rarely discussed during training.Both neurologists tackle the challenging question of whether three years of residency adequately prepares physicians for the growing complexity of neurological care. They explore innovative educational models, from specialty tracks to competency-based approaches, while emphasizing the critical importance of strong mentorship in visualizing diverse career paths.This conversation offers honest, practical guidance for navigating the post-residency landscape. Whether you're considering fellowship, direct practice, academic medicine, or industry roles, you'll gain valuable perspective on aligning your next steps with your true professional passions.Don't miss part two of this illuminating discussion, coming soon to the Neurophilia podcast. Subscribe now to continue exploring the transition to attending life with our experienced guests.Support the showHosts:Dr. Nupur Goel is a second-year neurology resident at Mass General Brigham in Boston, MA. Follow Dr. Nupur Goel on Twitter @mdgoels Dr. Blake Buletko is a vascular neurologist and program director of the Adult Neurology Residency Program at the Cleveland Clinic in Cleveland, OH. Follow Dr. Blake Buletko on Twitter @blakebuletko Follow the Neurophilia Podcast on Twitter and Instagram @NeurophiliaPod

In this episode, Steve Tringale, President of Mass General Brigham Health Plan, discusses the evolving landscape of healthcare, the challenges and opportunities brought by change, and how the organization is leveraging AI and integrated care to improve member outcomes and experiences. He also shares insights into leadership in a time of rapid industry transformation.

John Patrick Co is vice president of education at Mass General Brigham and an associate professor of pediatrics at Harvard Medical School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.F. Weinstein, E. Olson, and J.P.T. Co. Addressing Socioeconomic Barriers to Residency Choice. N Engl J Med 2025;392:1353-1355.

In this episode, Dr. Rebecca G. Mishuris, Chief Medical Information Officer and VP at Mass General Brigham, discusses the groundbreaking use of generative AI in ambient documentation. She shares how this technology is transforming clinician workflows, reducing burnout, and enhancing patient care—while also exploring the future of AI-driven healthcare innovation.

Send us a textHow can neurology education improve patient care? In this episode, we explore the significance of structured teaching, effective learning frameworks, and transferable skills that benefit students, trainees, and educators alike. Dr. Galina Gheihman, assistant professor of neurology at Harvard Medical School and neurologist at Mass General Brigham, shares insights on mentoring the next generation and the importance of educating the educators to amplify impact. Check out our website at www.theneurotransmitters.com to sign up for emails, classes, and quizzes! Would you like to be a guest or suggest a topic? Email us at contact@theneurotransmitters.com Follow our podcast channel on

In this episode, Heather O'Sullivan, APRN, President and COO of Healthcare at Home at Mass General Brigham, discusses the rapid expansion of the Home Hospital model, its impact on patient outcomes, and the challenges of scaling home-based acute care. She shares insights on how this innovative approach is addressing hospital capacity issues, enhancing workforce satisfaction, and shaping the future of healthcare.

This week on the Codcast, John McDonough of the Harvard T.H. Chan School of Public Health and Paul Hattis of the Lown Institute talk to Michael Barnett, who is both a primary care physician at Brigham and Women's Hospital and a professor of health policy at the T.H. Chan School, about the ongoing effort to unionize PCPs across the Mass General Brigham system.

Emerging cell and gene therapies represent areas of great promise for people with rare, genetic diseases, but the translation gap for these medicines can leave them stalled at the lab. Mass General Brigham in 2022 launched the Gene and Cell Therapy Institute, a research hub dedicated to advancing gene and cell therapies for various diseases to bridge the divide between academic labs and clinical development of therapies. The institute brings together more than 500 researchers and clinicians and boasts unique assets, such as its RNA Therapeutics Core, which enable it to produce cutting-edge circular RNA on-site. We spoke to Nathan Yozwiak, head of research at the Mass General Brigham Cell and Gene Therapy Institute, about the need it is seeking to address, how the institute operates, and what it might do to enable the development of bespoke therapies for ultra-rare diseases.

The first two episodes in this Healthcare is Hard podcast series on “Opportunities in Oncology” explored the relationship between academic medical centers and community care, with guests Dr. Stephen Schleicher from Tennessee Oncology, and Dr. Harlan Levine from City of Hope. For the third and final episode in the series, Dr. Daphne Haas-Kogan joined Keith Figlioli for a conversation that dives more deeply into patient care, innovations in care delivery and the opportunities for entrepreneurs.Dr. Haas-Kogan is Chair of the Department of Radiation Oncology at Mass General Hospital, Brigham and Women's Hospital, and Boston Children's Hospital. She is also the Willem and Corrie Hees Family Professor of Radiation Oncology at Harvard Medical School.Dr. Haas-Kogan received her undergraduate degree in biochemistry and molecular biology from Harvard University and her medical degree at UCSF. She completed her residency in radiation oncology at UCSF in 1997 and became vice-chair for research at UCSF in 2003, and educational program director in 2008. Dr. Haas-Kogan's laboratory research focuses on molecular underpinnings of brain tumors and pediatric cancers. She leads large multi-institutional initiatives funded by NIH/NCI, philanthropic organizations, and industry collaborators.For this episode of Healthcare is Hard, some of the topics Dr. Haas-Kogan discussed with Keith include:The collaborative approach to care. Dr. Haas-Kogan talked about how most people with cancer struggle with many other medical issues – some predating cancer diagnosis, some precipitated by the treatment itself – and how several care teams are required to treat the patient wholistically. She also discussed how important it is for academic medical centers and community hospitals to work together, the responsibilities each holds to the patient, and the goal of making sure patients receive the same exact care regardless of location.The precision of radiation oncology. There are generally three pillars of cancer treatment. The first is surgery to remove tumors, the second is medication to kill cancer cells with drugs, and the third is radiation therapy to destroy cancer cells. Dr. Haas-Kogan described how radiation oncology is, in many ways, a combination of surgical oncology and medical oncology. It requires the precision of surgery – especially when treating a tumor close to critical structures like the brain stem or spinal cord – but can also be applied in a single day or over the course of weeks, similar to medication. She discussed how this allows for unique collaboration between academic researchers and community physicians, along with opportunities for creative workforce solutions.AI in oncology. The impact artificial intelligence has already had on oncology would have been unimaginable five or 10 years ago, and Dr. Haas-Kogan says the opportunities for entrepreneurs in the space are huge. As an example of the impact AI has already made, she talked about how radiation oncologists traditionally spend hours defining exactly what they want treated and the dose of radiation required. But now, AI is doing most of that, saving physicians precious time. She talked about how medicine is an art and how treatment like this is very nuanced, so she very often makes changes after reviewing AI-generated recommendations. But she says advancements are coming quickly.To hear Dr. Haas-Kogan and Keith discuss these topics and more, listen to this episode of Healthcare is Hard: A Podcast for Insiders.

In this episode, Scott Becker breaks down eight major healthcare stories, including Mass General Brigham's layoffs, an Ohio hospital delaying payroll, rising measles cases in Texas, and a deep dive into healthcare billing fraud.

Is "leaky gut" real or just another wellness buzzword? In this episode of The Gut Health Podcast, we cut through the controversy with Dr. Alessio Fasano, a renowned gastroenterologist and microbiome expert from Mass General Brigham. Dr. Fasano explains what happens when the gut's protective barrier is compromised, resulting in increased intestinal permeability, and how this can affect not only gut health but also overall well-being. While some level of intestinal permeability is essential for health, in the presence of an altered gut microbiome, it can allow harmful molecules such as bacterial endotoxins and undigested food particles to pass through the intestinal lining. This can lead to inflammation, immune system activation, and may contribute to a variety of health issues, including autoimmune diseases, gastrointestinal disorders, heart disease, and more. We explore the molecular mechanisms that control intestinal permeability, examining how factors like epigenetic changes, diet, stress, and environmental factors can all impact the integrity of the gut barrier. Dr. Fasano breaks down the latest research on how intestinal permeability interacts with the immune system and other organ systems, highlighting the complex bidirectional relationship between gut health and overall wellness. Join us as we explore cutting-edge research on gut health, from breakthrough treatments to personalized diets and biomarkers for gut permeability. Tune in for expert insights and practical strategies—like a plant-forward diet and stress management—to strengthen your gut and overall well-being. References:Effects of dietary components on intestinal permeability in health and disease. Unfermented B-fructans Fibers Fuel Inflammation in Select Inflammatory Bowel Disease Patients. High FODMAP diet causes barrier loss via lipopolysaccharide-mediate mast cell activationA Randomized Placebo-Controlled Trial of Dietary Glutamine Supplements for Post-Infectious Irritable Bowel Syndrome.Bovine Colostrum in Increased Intestinal Permeability in Healthy Athletes and Patients: A Meta-Analysis of Randomized Clinical Trials. What to do about the leaky gut?Learn more about Kate and Dr. Riehl:Website: www.katescarlata.com and www.drriehl.comInstagram: @katescarlata @drriehl and @theguthealthpodcastOrder Kate and Dr. Riehl's book, Mind Your Gut: The Science-Based, Whole-body Guide to Living Well with IBS. The information included in this podcast is not a substitute for professional medical advice, examination, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider before starting any new treatment or making changes to existing treatment.

In Episode 34 of the Brand Slam podcast, co-hosts Joe Kayata and (add)ventures President Mary Sadlier sit down with Mark Bohen, Chief Marketing and Communications Officer at Mass General Brigham, to discuss the strategy behind one of the most significant healthcare rebrands in recent years. This effort went beyond introducing a new logo or brand identity—it was a strategic and high-stakes initiative to unify two world-renowned hospitals, Massachusetts General Hospital and Brigham and Women's Hospital, under a collaborative identity. Along with esteemed institutions like Spaulding Rehabilitation, McLean Hospital, and Mass Eye and Ear, the goal was to preserve their outstanding reputations while reinforcing a shared commitment to providing world-class patient care. Mark shares what it takes to transition from a network of independent hospitals to an integrated health system, highlighting the challenges of balancing brand identity, patient experience and internal collaboration. The conversation dives into how healthcare branding extends beyond names and logos—it requires buy-in from constituencies inside and outside the organization, as well as clear communication and sensitivity. As Mark explains, the objective was not only to unite the organization but also to reinforce the quality of care and expertise that patients associate with the brand. And with an established international presence and a reputation for world-class care, its branding had far-reaching implications. By investing in strategic communication and marketing, Mass General Brigham continues to strengthen its position as a global leader in healthcare. This episode offers an inside look at what it takes to bring a major healthcare brand into the future while staying true to its legacy. Interested in a particular topic or want to be a guest? Contact us at brandslam@addventures.com.

It's been an unusually tough winter virus season. Rates of flu-like infections are higher than they've been in nearly 30 years. And for the first winter since the start of the COVID-19 pandemic, flu deaths have surpassed COVID deaths. Add to that a higher-than-average year for norovirus, a nasty type of stomach bug.Then there's the emerging threat of avian flu. While there is no evidence of human-to-human transmission of the virus, about 70 people in the US have contracted the virus from livestock since April 2024.To make sense of the latest viral trends, Host Flora Lichtman talks with Dr. Katelyn Jetelina, epidemiologist and author of the newsletter “Your Local Epidemiologist”; and Dr. Erica Shenoy, chief of infection control at Mass General Brigham hospital.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Earlier this month Mass General Brigham hospital system announced its largest layoff in the organization's history, with an anticipated 1,500 job cuts. What are the implications for patient services at MGB? The two phased layoff comes at a time the country is facing a nationwide physician shortage. According to the Association of American Medical Colleges, the U.S. is facing a shortage of up to 124,000 physicians by 2034, including 48,000 primary care physicians. Dr. John Freedman, a health care expert joined us to discuss.Ask Alexa to play WBZ NewsRadio on #iHeartRadio and listen to NightSide with Dan Rea Weeknights From 8PM-12AM!

In this episode of the AJR Podcast Series on Training and Education, Marc Succi, MD, joins host Monica Cheng, MD, to discuss insights in healthcare innovation, from founding MESH Incubator at Mass General Brigham to exploring how leadership and education can foster innovation in radiology to meaningfully impact patient care.

NBC Sports Boston anchor/reporter Trenni Casey discusses the NBA All Star game,  booing at the Four Nations hockey tournament and the latest with White Stadium.Michael Curry of the League of Community Health Centers discusses major health cuts to NIH and here at Mass General Brigham, plus the NAACP's Black Consumer Advisory.Boston Globe business columnist Shirley Leung on Boston mayoral candidates already trading barbs around housing and conflicts of interest.CNN's John King joins remotely for the latest national political headlines.

The imPROVE study aims to bridge the gap in patient-reported outcomes (PRO) data for Black women with breast cancer by enhancing engagement with tailored electronic PROs (ePROs) and partnering with community leaders to address barriers and ensure accessibility and relevance in community cancer care settings. In this episode, CANCER BUZZ speaks with Manraj Kaur, PhD, investigator and lead faculty for research and innovation at Patient-Reported Outcomes, Value, and Experience (PROVE) center at Mass General Brigham and Andrea Pusic, MD, chief of division of plastic and reconstructive surgery, director of PROVE center at Mass General Brigham, and professor of surgery at Harvard Medical School about the imPROVE study's efforts to enhance Black women's engagement in ePROs in breast cancer treatment.  Dr. Kaur sheds light on strategies to improve technology accessibility for Black women in their cancer care center by providing iPads and refined usability features on the imPROVE app. Dr. Pusic highlights imPROVE implementation results at five community cancer centers, including utilizing local champions and equitable access to resources.   “When we make sure Black women are included, we gain a more accurate picture of health, we can design better care, and then we take a real step towards closing the health equity gap.” – Manraj Kaur   “The imPROVE study is all about increasing accessibility of patient-reported outcome measurements to Black breast cancer patients receiving care in community cancer centers.” – Andrea Pusic   Manraj Kaur, PhD   Investigator, Lead Faculty for Research and Innovation Patient-Reported Outcomes Value Experience (PROVE) Center  Brigham and Women's Hospital  Boston, MA    Andrea Pusic, MD  Chief of Division of Plastic and Reconstructive Surgery  Director, PROVE Center  Brigham and Women's Hospital  Professor of Surgery  Harvard Medical School  Boston, MA    Resources: ACCC imPROVE Study Blog - https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2024/06/18/the-power-of-patient-reported-outcome-measures-to-community-cancer-centers? Harvard/BWH PROVE Center - https://prove.bwh.harvard.edu/current_project/improve-breast-cancer-care/

Today, you're getting a masterclass about what alcohol does to your body, brain, and health. One of the most renowned and respected experts on alcohol is here to give you the latest research and science of how alcohol impacts your life. She's going to give you facts and help you be informed about the decisions you are making when it comes to your mental, physical, and emotional health when it comes to alcohol consumption. Joining Mel today is Harvard's Dr. Sarah Wakeman, MD. Dr. Wakeman is Senior Medical Director of Substance Use Disorder at Mass General Brigham, an Associate Professor of Medicine at Harvard Medical School, and the Program Director of Mass General Substance Use Addiction Services. She's here to answer: How much is TOO much alcohol? What amount of alcohol is okay in a healthy life? What happens to your brain when you drink? And how do you help someone you love who you think drinks too much? By the time you finish listening, you'll have the latest research so that you make the most informed decisions about the role alcohol plays in your life. This is an encore episode with new and exciting insights from Mel at the top. Join Mel on her first ever LIVE tour, Let Them The Tour, here.Get a copy of Mel's new book, The Let Them Theory here. For more resources, including links to Dr. Sarah Wakeman's work, click here for the podcast episode page. If you liked this episode, your next listen should be this one: Harvard Psychologist Shares 6 Words That Will Change Your Family Connect with Mel:  Get Mel's new book, The Let Them TheoryWatch the episodes on YouTubeFollow Mel on Instagram The Mel Robbins Podcast InstagramMel's TikTok Sign up for Mel's personal letter Subscribe to SiriusXM Podcasts+ on Apple Podcasts to listen to ad-free new episodes Disclaimer